echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Zhongsheng Pharmaceutical's new drug application for the treatment of squamous non-small cell lung cancer with Paampril has been accepted

    Zhongsheng Pharmaceutical's new drug application for the treatment of squamous non-small cell lung cancer with Paampril has been accepted

    • Last Update: 2021-08-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 2, China Biopharmaceuticals issued an announcement stating that the anti-PD-1 monoclonal antibody drug "Paampril" jointly developed by the group and Kangfang Biotechnology (Cayman) Co.


    A few days ago, Pianpril has passed the new real-time tumor review (RTOR) policy for the third-line treatment of metastatic nasopharyngeal carcinoma, and submitted a biologics license application (BLA) to the US FDA


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.